Peter Frederik Horstmann

Peter Frederik Horstmann

Auto-generated profile, based on publicly available information

Peter Frederik Horstmann

Musculoskeletal Tumor Section, Department of Orthopedic Surgery, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2018 in International Orthopaedics
Verified
Journal Article
Closed access
PDF file
CHChristina Enciso Holm
Christina Enciso Holm
CBChristian Bardram
Christian Bardram
ARAnja Falk Riecke
Anja Falk Riecke
PHPeter Horstmann
Peter Horstmann
Michael Mørk PetersenMichael Mørk Petersen
Michael Mørk Petersen

1 December 2017 in Tissue Engineering Part A
Verified
Journal Article
Closed access
PHPeter Frederik Horstmann
Peter Frederik Horstmann
Deepak RainaDeepak Raina
Deepak Raina
HIHanna Isaksson
Hanna Isaksson
WHWerner Hettwer
Werner Hettwer
LLLars Lidgren
Lars Lidgren
MTMagnus Tägil
Magnus Tägil
Restoring lost bone is a major challenge in orthopedic surgery. Currently available treatment strategies have shortcomings, such as risk of infection, nonunion, and excessive resorption. Our primary aim was to study if a commercially available gentamicin-containing composite calcium sulfate/hydroxyapatite biomaterial (GBM) could serve as a carrier for local delivery of bone morphogenic protein-2 (BMP-2) and zoledronic acid (ZA) in a tibia defect model in rats. Empty and allograft-filled defects were used as controls. A 3 × 4-mm metaphyseal bone defect was created in the proximal tibia, and the rats were grouped according to defect filling: (1) Empty, (2) Allograft, (3) GBM, (4) GBM + ZA, and (5) GBM + ZA + BMP-2. In vivo microcomputed tomography (micro-CT) images at 4 weeks showed significantly higher mineralized tissue volume (MV) in the intramedullary defect region and the neocortical/callus region in all GBM-treated groups. After euthanization at 8 weeks, ex vivo micro-CT showed that addition of ZA (GBM + ZA) and BMP-2 (GBM + ZA + BMP-2) mainly increased the neocortical and callus formation, with the highest MV in the combined ZA and BMP-2-treated group. Qualitative histological analysis, verifying the increased neocortical/callus thickness and finding of trabecular bone in all GBM-treated groups, supported that the differences in MV measured with micro-CT in fact represented bone tissue. In conclusion, GBM can serve as a carrier for ZA and BMP-2 leading to increased MV in the neocortex and callus of a metaphyseal bone defect in rats.

1 September 2018 in Journal of Orthopaedic Surgery
Verified
Journal Article
Open access
PHPeter F Horstmann
Peter F Horstmann
WHWerner H Hettwer
Werner H Hettwer
MPMichael M Petersen
Michael M Petersen
The management of bone defects following simple curettage of bone tumors is controversial and in light of the numerous emerging substitutes for bone grafts, we wished to review and report our experience with the use of cancellous allograft bone in the treatment of benign and borderline bone tumors. We reviewed the medical records of 164 consecutive patients with benign or borderline bone tumors treated with simple curettage at our orthopedic oncology center between 2009 and 2013. Postoperative radiological changes were evaluated by a modified Neer’s classification in defects that were subsequently reconstructed with allograft bone (n = 133). Simple curettage with subsequent defect filling using allograft bone was the surgical procedure performed in the majority of our patients (81%) and was associated with a low overall 2.5-year local recurrence (LR; 9.8%) and complication rate (7.5%). The radiological appearance of the grafted defects was deemed satisfactory in 85% of cases, with signs of either complete or partial healing present 6–12 months postoperatively. With respect to pathology, we found high rates of LR in giant cell tumors (GCTs) of bone, simple cysts (SCs) in children, and preexisting local recurrent disease. We did not observe any allograft-related complications. Simple curettage and bone defect reconstruction with bone allograft is a sufficient treatment for most benign bone lesions and is associated with a low complication rate. For high-risk entities, such as GCTs of bone, SCs in children, and recurrent disease, additional adjuvant treatment could be considered to avoid LR.

18 October 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
PHPeter Frederik Horstmann
Peter Frederik Horstmann
WHWerner Herbert Hettwer
Werner Herbert Hettwer
NKNicolai Stefan Kaltoft
Nicolai Stefan Kaltoft
MPMichael Mørk Petersen
Michael Mørk Petersen
Substitutes for bone grafts experience increasing popularity, but the need for defect-filling following simple curettage of benign bone lesions is controversial. In this study, we wish to objectively report the radiological changes following bone defect-filling using a composite ceramic bone graft substitute, as well as the clinical results and complications. We evaluated 35 surgically treated benign bone lesions with subsequent defect-filling using two variants of a composite ceramic bone graft substitute (CERAMENT|BONE VOID FILLER or CERAMENT|G, BONESUPPORT AB, SWEDEN). After one year, a normal cortical thickness surrounding the defect was seen in approximately 80% of patients. Inside the defect-cavity, an almost complete product-resorption was seen after one year. The most common complication was a post-operative inflammatory soft-tissue reaction, seen in 7 patients (20%), which resolved without further treatment, although short-term antibiotic treatment was initiated at a local hospital in 6 patients, due to suspected wound infection. In summary, cortical thickness most commonly normalizes after bone tumor removal and filling of the bone defect using this particular composite ceramic bone graft substitute. The ceramic substitute undergoes resorption, which causes progressive changes in the radiological appearance inside the bone defect.

1 February 2014 in European Journal of Trauma and Emergency Surgery
Verified
Journal Article
Closed access
PDF file
PHP. Horstmann
P. Horstmann
CLC. F. Larsen
C. F. Larsen
HGH. Grønborg
H. Grønborg

7 June 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MSMichala Skovlund Sørensen
Michala Skovlund Sørensen
TCThomas Colding-Rasmussen
Thomas Colding-Rasmussen
PHPeter Frederik Horstmann
Peter Frederik Horstmann
KHKlaus Hindsø
Klaus Hindsø
CDChristian Dehlendorff
Christian Dehlendorff
Michael Mørk PetersenMichael Mørk Petersen
Michael Mørk Petersen
Background: Plasma IL-6 and YKL-40 are prognostic biomarkers for OS in patients with different types of solid tumors, but they have not been studied in patients before surgery of metastatic bone disease (MBD) of the extremities. The aim was to evaluate the prognostic value of plasma IL-6 and YKL-40 in patients undergoing surgery for MBD of the extremities. Patients and Methods: A prospective study included all patients undergoing surgery for MBD in the extremities at a tertiary referral center during the period 2014–2018. Preoperative blood samples from index surgery were included. IL-6 and YKL-40 concentrations in plasma were determined by commercial ELISA. A total of 232 patients (median age 66 years, IQR 58–74; female 51%) were included. Results: Cox regression analysis was performed to identify independent prognostic factors for OS. IL-6 correlated with YKL-40 (rho = 0.46, p < 0.01). In univariate analysis (log2 continuous variable) IL-6 (HR = 1.26, 95% CI 1.16–1.37), CRP (HR = 1.20, 95% CI 1.12–1.29) and YKL-40 (HR = 1.25, 95% CI 1.15–1.37) were associated with short OS. In multivariable analysis, adjusted for known risk factors for survival, only log2(IL-6) was independently associated with OS (HR = 1.24, 95% CI 1.08–1.43), whereas CRP and YKL-40 were not. Conclusion: High preoperative plasma IL-6 is an independent biomarker of short OS in patients undergoing surgery for MBD.